Ali S Alzahrani1,2, Meshael Alswailem3, Balgees Alghamdi3, Rafiullah Rafiullah4, Mohammed Aldawish5, Hindi Al-Hindi6. 1. Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. aliz@kfshrc.edu.sa. 2. Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. aliz@kfshrc.edu.sa. 3. Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 4. Center of Genomic Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 5. Endocrinology & Diabetes Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 6. Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Abstract
CONTEXT: RET p.V804M is classified as a moderate risk mutation for familial medullary thyroid cancer (FMTC). There is a significant controversy on the management of patients carrying this mutation. We describe a family incidentally discovered to have this mutation and review the literature on RET p.V804M mutation. RESULTS: The proband was born to first-degree relative parents. He was noticed to have hypertrophy of some parts of the body and vascular skin changes. Whole-exome sequencing of DNA extracted from a skin biopsy showed a mutation in the PIK3CA (c.3132T>G, p.ASN1044LYS). This variant was not found in DNA extracted from blood. This confirmed the diagnosis of CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi and Scoliosis, skeletal or spinal anomalies). Another incidentally found mutation in the skin biopsy and blood sample was RET p.V804M. Although there was no family history of MTC or MEN 2 syndromes, family screening revealed RET p.V804M mutation and FMTC in the proband's father, paternal grandmother, one sister, and one aunt. There was significant interfamilial heterogeneity in the age of presentation and pathology. A review of literature showed that RET p.V804M mutation is a moderate risk mutation associated with late-onset FMTC, usually at middle to old age. CONCLUSION: Despite the controversy and the heterogeneous presentation of patients with RET p.V804M mutation, our study and review of the literature suggest that this seemingly "low" risk mutation is associated with late-onset but potentially aggressive MTC. This indicates the need for follow-up and timely intervention based on calcitonin level elevation.
CONTEXT: RET p.V804M is classified as a moderate risk mutation for familial medullary thyroid cancer (FMTC). There is a significant controversy on the management of patients carrying this mutation. We describe a family incidentally discovered to have this mutation and review the literature on RET p.V804M mutation. RESULTS: The proband was born to first-degree relative parents. He was noticed to have hypertrophy of some parts of the body and vascular skin changes. Whole-exome sequencing of DNA extracted from a skin biopsy showed a mutation in the PIK3CA (c.3132T>G, p.ASN1044LYS). This variant was not found in DNA extracted from blood. This confirmed the diagnosis of CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi and Scoliosis, skeletal or spinal anomalies). Another incidentally found mutation in the skin biopsy and blood sample was RET p.V804M. Although there was no family history of MTC or MEN 2 syndromes, family screening revealed RET p.V804M mutation and FMTC in the proband's father, paternal grandmother, one sister, and one aunt. There was significant interfamilial heterogeneity in the age of presentation and pathology. A review of literature showed that RET p.V804M mutation is a moderate risk mutation associated with late-onset FMTC, usually at middle to old age. CONCLUSION: Despite the controversy and the heterogeneous presentation of patients with RET p.V804M mutation, our study and review of the literature suggest that this seemingly "low" risk mutation is associated with late-onset but potentially aggressive MTC. This indicates the need for follow-up and timely intervention based on calcitonin level elevation.
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: V Rohmer; G Vidal-Trecan; A Bourdelot; P Niccoli; A Murat; J L Wemeau; F Borson-Chazot; C Schvartz; A Tabarin; O Chabre; G Chabrier; P Caron; P Rodien; M Schlumberger; E Baudin Journal: J Clin Endocrinol Metab Date: 2010-12-29 Impact factor: 5.958
Authors: L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi Journal: Nature Date: 1993-06-03 Impact factor: 49.962
Authors: A Bolino; I Schuffenecker; Y Luo; M Seri; M Silengo; T Tocco; G Chabrier; C Houdent; A Murat; M Schlumberger Journal: Oncogene Date: 1995-06-15 Impact factor: 9.867
Authors: Rui M B Maciel; Cleber P Camacho; Lígia V M Assumpção; Natassia E Bufalo; André L Carvalho; Gisah A de Carvalho; Luciana A Castroneves; Francisco M de Castro; Lucieli Ceolin; Janete M Cerutti; Rossana Corbo; Tânia M B L Ferraz; Carla V Ferreira; M Inez C França; Henrique C R Galvão; Fausto Germano-Neto; Hans Graf; Alexander A L Jorge; Ilda S Kunii; Márcio W Lauria; Vera L G Leal; Susan C Lindsey; Delmar M Lourenço; Léa M Z Maciel; Patrícia K R Magalhães; João R M Martins; M Cecília Martins-Costa; Gláucia M F S Mazeto; Anelise I Impellizzeri; Célia R Nogueira; Edenir I Palmero; Cencita H C N Pessoa; Bibiana Prada; Débora R Siqueira; Maria Sharmila A Sousa; Rodrigo A Toledo; Flávia O F Valente; Fernanda Vaisman; Laura S Ward; Shana S Weber; Rita V Weiss; Ji H Yang; Magnus R Dias-da-Silva; Ana O Hoff; Sergio P A Toledo; Ana L Maia Journal: Endocr Connect Date: 2019-03-01 Impact factor: 3.335